Search research articles
Contact Us
Filters
Showing results (51-60 of 55) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 55 results.
Antimicrobial Agents and Chemotherapy
|
September 22, 2010
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production
Jennifer H Moffatt, Marina Harper, Paul Harrison, et al.
Antimicrobial Agents and Chemotherapy
|
July 10, 2023
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance
Jessica R Tait, Marina Harper, Sara Cortés-Lara, et al.
International Journal of Antimicrobial Agents
|
April 1, 2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
Siobhonne K J Breen, Marina Harper, Carla López-Causapé, et al.
The Lancet. Microbe
|
June 25, 2026
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, et al.
Antimicrobial Agents and Chemotherapy
|
May 2, 2018
Emergence of High-Level Colistin Resistance in an Acinetobacter baumannii Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS
Deanna Deveson Lucas, Bethany Crane, Amy Wright, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 55) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 55 results.
Antimicrobial Agents and Chemotherapy
|
September 22, 2010
Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production
Jennifer H Moffatt, Marina Harper, Paul Harrison, et al.
Antimicrobial Agents and Chemotherapy
|
July 10, 2023
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance
Jessica R Tait, Marina Harper, Sara Cortés-Lara, et al.
International Journal of Antimicrobial Agents
|
April 1, 2024
Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing
Siobhonne K J Breen, Marina Harper, Carla López-Causapé, et al.
The Lancet. Microbe
|
June 25, 2026
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations
Siobhonne K J Breen, Sara Cortés-Lara, Jessica R Tait, et al.
Antimicrobial Agents and Chemotherapy
|
May 2, 2018
Emergence of High-Level Colistin Resistance in an Acinetobacter baumannii Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS
Deanna Deveson Lucas, Bethany Crane, Amy Wright, et al.
Page
of 6